ClinicalTrials.gg
RecruitingNCT06638268TACTICSUpdated Apr 22, 2026

Transcatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock

An interventional study of Acute TAVI and Stabilization and subacute TAVI in Aortic Stenosis and Cardiogenic Shock, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.

Planned enrollment
36th of 40
30 · median 214
Started
2024
with 6 others
No phase
28 of 73
7 open now
Primary completion
2027-07
later than 18 of 27 live
Registered
69th of 73
by date
Lead sponsor
7 of 73
Rigshospitalet, Denmark

Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 36th largest by planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2024, is one of 28 with no phase, reaches primary completion later than 18 of the 27 other live ones, and was the 69th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Aortic Valve Stenosis with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if acute transcatheter aortic valve implantation (TAVI) is superior to standard treatment (stabilization in an intensive care unit and TAVI subsequently) to treat cardiogenic shock in patients with critical severe aortic stenosis.

The main questions it aims to answer are:

  • Does acute TAVI increase survival compared with standard treatment?

Participants will:

  • Undergo either TAVI within 12 hours after admission or stabilization and TAVI 72 hours or more after admission
  • Visit an outpatient clinic and be evaluated for quality of life and heart function
Read the detailed description

Aortic stenosis (AS) is a condition where the heart's aortic valve narrows. With an estimated prevalence of 12% in individuals aged 75 years and above, it is the most common heart valve disease. The progressive narrowing increases the afterload on the heart, impairing its ability to maintain cardiac output. The end-stage of critical AS is cardiogenic shock (CS) with an incidence of 3.5% to 12%. Without treatment, patients develop acute decompensation, organ failure, and ultimately die.

Guidelines suggest balloon aortic valvuloplasty (BAV), hemodynamic optimization in the intensive care unit and surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) when the patient is stable. Even with BAV, the 30-day mortality is 33%-47% and a 1-year mortality is 70%. Further, the BAV procedure is associated with only a minor and likely temporary reduction in afterload due to elastic valvular tissue. Furthermore, the BAV procedure has been abandoned as a routine intervention in these patients due to a series of patients having limited immediate clinical response, a risk of deterioration and no impact on overall mortality risk. Moreover, most patients with critical AS in CS are not candidates for surgical aortic valve replacement because of increased peri-operative risk of morbidity and mortality.

Despite the recommendation on TAVI under stable conditions, an acute TAVI may be efficient in afterload reduction and more efficient than the limited and transient effects of BAV. TAVI has become an attractive alternative to surgery and BAV because of the less invasive nature of this procedure, yet permanent result (compared with BAV). It is already approved for the treatment of AS irrespective of CS status. This raises the question:

"Should acute TAVI be the new preferred treatment strategy in AS patients in Cardiogenic shock?"

In this randomized controlled trial, we will include patients with severe aortic stenosis and cardiogenic shock. Patients will undergo either acute TAVI or standard treatment (stabilization in a cardiac intensive care unit and subsequently TAVI) in a 1:1 ratio. Outcomes are evaluated 90 days after randomization and comprise days alive out of hospital, mortality, cardiac function, renal function, and quality of life.

03

Conditions studied

  • Aortic Stenosis
  • Cardiogenic Shock

Keywords

  • Randomized Controlled Trial
  • Cardiogenic Shock
  • Aortic Stenosis
  • Mortality
  • Frailty
  • Quality Of Life
  • Aortic Valve Stenosis
  • Transcatheter Aortic Valve Replacement
  • Transcatheter Aortic Valve Implantation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aortic valve area less than 1cm2

AND

Cardiogenic Shock defined as:

  • Peripheral signs of tissue hypoperfusion (arterial blood lactate ≥2.5mmol/l) AND
  • Systolic blood pressure \< 100 mmHg and/or need for vasopressor therapy (dopamine/ norepinephrine or epinephrine) AND
  • ≤ 45%

OR

- Syncope/resuscitation (mechanical ventilation)

Exclusion criteria

Exclusion Criteria:

  • Intracranial hemorrhage \< 1 month ago
  • Remaining life-expectancy \< 6 month due to other cause
  • \<15 OR > 40
  • Clinical frailty score ≥6 before present worsening
  • Severe lung disease ( OR diffusion capacity of the lungs for carbon monoxide \< 25 of expected)
  • Unsuitable for TAVI prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Acute TAVI

    Acute TAVI within 12 hours.

    Procedure: Acute TAVI

  • Active comparator
    Standard treatment

    TAVI no earlier than 72 hours.

    Other: Stabilization and subacute TAVI

Interventions

  • ProcedureAcute TAVI

    TAVI must be performed as soon as possible and within 12 hours of admission to the heart center.

  • OtherStabilization and subacute TAVI

    Patients are stabilized according to target parameters. Treatment may include vasopressor, mechanical ventilation, renal replacement therapy, and blood transfusion. TAVI is then performed no earlier than 72 hours of admission to heart center.

06

What researchers measure

Primary outcomes

  1. Days alive out of hospital

    Days alive out of hospital

    Time frame: 90 days post-randomization

Secondary outcomes

  1. Mortality

    Rate of all-cause mortality

    Time frame: 90 days post-randomization

  2. LVEF

    Left ventricular ejection fraction assessed with transthoracic echocardiography

    Time frame: 90 days post-randomization

  3. Clinical Frailty Scale

    The Clinical Frailty Scale (CFS) is a tool used to assess a patient\&#39;s level of frailty. The CFS ranges from 1 to 9, with higher scores indicating greater frailty.

    Time frame: 90 days post-randomization

  4. EQ-5D-5L

    The EQ-5D-5L is a standardized instrument used to measure health-related quality of life. It is designed for use in clinical settings, research, and health evaluations, and provides a simple, yet comprehensive measure of a patient\&#39;s overall health status. The \&#34;5D\&#34; refers to the five dimensions of health that it assesses, and the \&#34;5L\&#34; refers to the five levels of severity within each dimension.

    Time frame: 90 days post-randomization

  5. N-terminal-pro-brain- natriuretic peptide levels

    Meassured in a blood sample

    Time frame: 90 days post-randomization

  6. eGFR

    Estimated glomerular filtration rate in mL/min/1.73m2 meassured in a blood sample.

    Time frame: 90 days post-randomization.

07

Study locations

1 of 1 sites recruiting
  • Rigshospitalet Copenhagen University Hospital
    Copenhagen O, 2100, Denmark
    Recruiting
    • Emil L Fosbøl, Professor, MD, PhD · Contactemil.fosboel@regionh.dk · 004535456340
    • Emil L Fosbøl, Professor, MD, PhD · Principal investigator
    • Jesper Kjærgaard, Associate professor, DMSc, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 31 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Nov 25, 2024
Primary completionEst.
Jul 1, 2027
CompletionEst.
Oct 30, 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06638268
Responsible party
Emil Loldrup Fosbol (Professor, Rigshospitalet, Denmark) — Principal investigator
First posted
Oct 15, 2024
Start date
Nov 25, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Apr 22, 2026

Study contacts

Emil L Fosbøl, Professor, MD, PhD
Contact
emil.fosboel@regionh.dk
004535456340
Jarl E Strange, MD, PhD
Contact
jarl.emanuel.strange.02@regionh.dk
004560616598

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion